Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug testing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,069 result(s) found for: Drug testing. Displaying page 3 of 104.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-000322-66 Sponsor Protocol Number: CRAD001A2433 Start Date*: 2013-11-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibi...
    Medical condition: Adult kidney transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) SK (Completed) ES (Completed) PT (Completed) AT (Completed) NL (Completed) BE (Completed) GR (Completed) CZ (Completed) SI (Completed) BG (Completed) PL (Completed) HR (Completed) NO (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003431-29 Sponsor Protocol Number: CBGG492A2216 Start Date*: 2014-05-27
    Sponsor Name:Novartis Farma S.p.A.
    Full Title: A multicenter medical safety follow-up study for patients with partial onset seizures who received more than 28 days of total exposure to BGG492 in studies CBGG492A2207 and/or CBGG492A2212.
    Medical condition: Testing for adrenal cortical adenomas in male and female patients Testing for uterine endometrial stromal sarcromas in all female patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004412-12 Sponsor Protocol Number: CLAF237B2201 Start Date*: 2009-02-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as monotherapy in patients with type 2 diabetes
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000691-11 Sponsor Protocol Number: 89303200 Start Date*: 2022-01-18
    Sponsor Name:Rigshospitalet
    Full Title: Comparison of the effect of xylometazoline and cocaine on epistaxis when administered as local vasoconstrictors prior to nasal intubation
    Medical condition: Epistaxis upon nasal intubation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-004993-26 Sponsor Protocol Number: CSPP100A2351 Start Date*: 2006-05-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A nine-week, randomized, double-blind, parallel group study to evaluate the efficacy and safety of aliskiren 300 mg, compared to irbesartan 300 mg and ramipril 10 mg in the setting of a missed dose...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.1 10020772
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) IT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003814-37 Sponsor Protocol Number: AKF-400 Start Date*: 2021-11-29
    Sponsor Name:Odense University Hosipital
    Full Title: The effect of dicloxacillin on oral absorption of drugs
    Medical condition: Healthy volunteers. (Dicloxacillin is used against infections caused by beta-lactamase-producing organisms) Testing for drug-drug interactions caused by dicloxacillin.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002461-18 Sponsor Protocol Number: 20-214-36 Start Date*: 2022-01-14
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head a...
    Medical condition: Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) HU (Completed) ES (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000054-37 Sponsor Protocol Number: ITM0514 Start Date*: 2015-07-06
    Sponsor Name:Institute of Tropical Medicine
    Full Title: Be-PrEP-ared: HIV prevention with Pre-exposure prophylaxis – a demonstration project in high risk men having sex with men in Belgium
    Medical condition: HIV prevention
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017063-42 Sponsor Protocol Number: ML22606 Start Date*: 2010-12-07
    Sponsor Name:Roche Romania SRL
    Full Title: Biomarkers Impact On the response to Treatment with Erlotinib in first line non-small cell lung Cancer with EGFR activating mutations
    Medical condition: Non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-023331-42 Sponsor Protocol Number: IMIOXC Start Date*: 2010-12-15
    Sponsor Name:Department of Neurology, Odense University Hospital
    Full Title: Oxcarbazepine for the treatment of chronic peripheral neuropathic pain: predictors of response - a randomised, double-blind, placebo-controlled clinical trial
    Medical condition: Chronic peripheral neuropathic pain caused by polyneuropathy, postherpetic neuralgia and traumatic/surgical nerve injury.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023375-26 Sponsor Protocol Number: SYDNEY_Sildenafil_Version_1.8.2011 Start Date*: 2012-06-27
    Sponsor Name:Medizinische Universität Wien, Klinik für Innere Medizin II, Abteilung für Kardiologie
    Full Title: Effects of Sildenafil on Signs and SYmptoms of Ischemia, Myocardial BlooD Flow, and Markers of ANgiogenesis in Patients with REfractory CoronarY Artery Disease (SYDNEY) A Randomized, Double-Blind,...
    Medical condition: Patients with coronary artery disease who suffer from myocardial malperfusion and continue to experience angina despite maximal medical and revascularization therapy are called "no-option" patients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002466-38 Sponsor Protocol Number: CLAF237A2329 / CLAF237A2329E1 Start Date*: 2004-11-01
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with ...
    Medical condition: Diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2022-003201-30 Sponsor Protocol Number: 1.0-03.10.2022 Start Date*: 2022-12-22
    Sponsor Name:Medical University Vienna
    Full Title: The Impact of Biological Gender in Peripheral Nerve Blockade: A Prospective Study in Volunteers
    Medical condition: To evaluate pharmacodynamic, pharmacokinetic and nerve-related morphometric differences of biological gender (male versus female) on nerve block characteristics
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000692-32 Sponsor Protocol Number: FARMPre-Proposalcode:TRS-2016-00 Start Date*: 2019-07-17
    Sponsor Name:DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
    Full Title: EFFICACY OF METFORMIN ON MOTILITY AND STRENGTH IN MYOTONIC DYSTROPHY TYPE 1. A randomized, double blind, placebo-controlled, multicenter clinical trial.
    Medical condition: Myotonic Distrophy type 1, confirmed by genetic testing, with a CTG expansion size >100
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068871 Myotonic dystrophy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10013987 Dystrophia myotonica LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002899-25 Sponsor Protocol Number: CQVM149B2302 Start Date*: 2015-12-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, 52-week, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) DE (Completed) SK (Completed) PT (Completed) AT (Completed) HU (Completed) NL (Completed) FI (Completed) BE (Completed) ES (Completed) DK (Completed) LV (Completed) GR (Completed) FR (Completed) BG (Completed) IE (Completed) HR (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022658-18 Sponsor Protocol Number: CLAF237A23150 Start Date*: 2011-04-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients ≥ 70 years (drug-...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) SK (Completed) DE (Completed) BG (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-002864-24 Sponsor Protocol Number: UMCN-AKF 06.02 Start Date*: 2006-09-25
    Sponsor Name:Dept. of Clinical Pharmacy, Radboud UMC Nijmegen, The Netherlands
    Full Title: Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA)
    Medical condition: malaria prophylaxis in HIV patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025494 Malaria prophylaxis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-005045-35 Sponsor Protocol Number: CLAF237A2327 Start Date*: 2005-02-17
    Sponsor Name:Novartis Sverige AB
    Full Title: A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetes
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005182-35 Sponsor Protocol Number: BO20906 Start Date*: 2008-06-20
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chem...
    Medical condition: Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IE (Prematurely Ended) LV (Prematurely Ended) ES (Completed) BE (Prematurely Ended) AT (Completed) SK (Completed) CZ (Completed) HU (Prematurely Ended) PT (Prematurely Ended) EE (Prematurely Ended) SE (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003249-25 Sponsor Protocol Number: ATLANTIS_2015 Start Date*: 2016-11-28
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. University of Glasgow
    Full Title: An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer.
    Medical condition: Metastatic urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10061620 Adenocarcinoma with transitional cell carcinoma of bladder LLT
    21.0 100000004864 10001213 Adenocarcinoma with transitional cell carcinoma of bladder NOS LLT
    21.1 100000004864 10001214 Adenocarcinoma with transitional cell carcinoma of bladder recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 18:51:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA